TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 29, 2017

Study Completion Date

September 29, 2017

Conditions
Glioblastoma Multiforme (GBM)
Interventions
DRUG

Mibefradil with Radiation

"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."

Trial Locations (1)

06520

Yale University, New Haven

All Listed Sponsors
collaborator

Yale University

OTHER

lead

Cavion, Inc.

INDUSTRY

NCT02202993 - TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | Biotech Hunter | Biotech Hunter